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Arjun Patel
Family Medicine Clerkship October-November 2018
WCHN Southbury Primary Care
Preceptor: Dr. Agata Poznanska

Problem Identification and Description of
Need
• Shingles (herpes zoster) affects approximately 1 in 3 people during their lifetime.
Shingles affects half of all people who live to the age of 85 or older.1
• Within the last year, the CDC has recommended that most adults 50 and older
should get the new shingles vaccine, Shingrix
• In adults 50 to 69 years old who got two doses, Shingrix was 97% effective in preventing
shingles; among adults 70 years and older, Shingrix was 91% effective.
• In adults 50 to 69 years old who got two doses, Shingrix was 91% effective in preventing postherpetic neuralgia; among adults 70 years and older, Shingrix was 89% effective.2

• The vast majority of the patients at our practice in Southbury, CT are above the
age of 50. Many are unaware of this vaccine and/or have misconceptions about
the vaccine, especially concerning past vaccination for shingles or prior episodes
of shingles and chickenpox
• As a result, we spend significant time during appointments each day educating patients on
the new vaccine, when we could be addressing other concerns

Public Health Cost
• In the United States, herpes zoster and related complications are
estimated to result in approximately $1.3 billion in medical care costs
and $1.7 billion in indirect costs annually.3
• These costs can be expected to increase over time due to the aging
population in the U.S.
• The number of adults over the age of 65 is expected to surpass the number of
children (individuals under the age of 18) by 2035.4

Community Perspective
• A provider at our practice spoke about their experience treating patients with
shingles, noting that sometimes those vaccinated with Zostavax would still get
shingles. However, some of the patients who had been previously vaccinated
seemed to have less severe episodes of shingles than unvaccinated individuals.
The provider also emphasized the importance of the Shingrix vaccine being
inactivated instead of a live virus, so that
immunocompromised/immunosuppressed patients who are at higher risk of
experiencing shingles can now get the vaccine.
• A provider at a community health clinic in the Southbury area stated that it is
important for patients to know that the Shingrix vaccine is recommended after
the age of 50 regardless of whether a patient remembers having chickenpox or
shingles in the past, and regardless of whether they had Zostavax. The provider
said that soreness at the injection site is generally a normal side effect and should
not be a reason to avoid getting the second dose of Shingrix.

Intervention and Methodology
• Intervention
• Create a brief, easy to understand handout to educate patients at our practice
about the Shingrix vaccine. The handout concisely summarizes patientrelevant information about shingles and the vaccine. The handout will be
made available in the waiting area and exam rooms.

• Methodology
• Researched CDC data and peer reviewed publications for information to
include in the handout
• Spoke with local providers about their experiences with shingles and shingles
vaccines to evaluate what information would be most beneficial to patients
• Recorded commonly asked questions by patients during the rotation to
include in the handout

Results
• The result is a 2-sided single page handout briefly addressing what
shingles and post-herpetic neuralgia are, with a frequently asked
questions section.
• The handout is awaiting approval for use in clinic from WCHN
administration. The plan is to make it available to patients in the
waiting area and exam rooms in the clinic and potentially other clinics
in the network.

Evaluation of effectiveness and limitations
• Proposed evaluation of effectiveness

• Provide patients with handout before their appointment and determine if they have further
questions about the Shingrix vaccine before receiving it in office or at a pharmacy. Note what
questions patients still have about the vaccine and address these questions in future versions
of the handout.
• Patients who are presenting for follow-up visits or physicals could either be offered the
handout or not offered handout at random when they check-in for their appointment. When
the Shingrix vaccine is discussed with them during the appointment, the amount of time
spent discussing this topic could be compared between the two groups. Completion of the
vaccination series could also be compared between the two groups.

• Limitations

• The current national shortage of the vaccine may make it difficult for patients to receive the
vaccine in the office or in pharmacies, regardless of motivation.
• Differences in insurance coverage can affect how easy it is to get the vaccine.
• Prior shingles infection or vaccination with Zostavax may influence a patient’s motivation to
receive the Shingrix vaccine.

Recommendations for future interventions
• Add more detailed information to the handout concerning insurance
coverage
• Convert the handout into an electronic form that can be sent to the
patient after a visit
• More active engagement of the community, perhaps with a
presentation about the vaccine at local assisted living facilities where
they can ask questions and also receive the handout
• Implementation of a trial to determine the effectiveness of the
handout at multiple sites in the area, as described in the ‘Evaluation
of effectiveness and limitations’ slide
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